Filtrer par catégorie
- Tous
- Congress
- Blog
- Congrès
- Ressource Scientifique
- Webinaire
- Poster
- Publication scientifique
- Communiqué de Presse
- Couverture presse
- Actualités
Filtrer par catégorie
Blog
02/02/2023
Why do preclinical cancer models still fail in the clinic?
We at Oncodesign Services strive to develop alternative Preclinical Cancer Models to better suit your drug development. Read more about our solutions here.
Actualités
19/01/2023
Oncodesign S.A. is now Oncodesign Services S.A.
Oncodesign Services is chane announced the change of name to Oncodesign Services and a new COMEX for 2023.
Publication scientifique
16/01/2023
Liposomal Irinotecan Shows a Larger Therapeutic Index than Non-liposomal Irinotecan in Patient-Derived Xenograft Models of Pancreatic Cancer
Liposomal Irinotecan is hypothesized to have a higher therapeutic index than its non-liposomal counterpart in mice with Pancreatic Cancer. Read more here.
Actualités
14/12/2022
Oncodesign Services looks to the future
As Oncodesign evolves into Oncodesign Services and begins its journey as an independent business, CEO Fabrice Viviani explains his hopes and plans for the company’s future
Publication scientifique
25/11/2022
Calcium(II)-Catalyzed Chemoselective and Regioselective Epoxide Ring-Opening with NH Sulfoximines
In this paper we describe methods for the Organic Synthesis of 1,2-sulfoximidoyl ethanols thanks to an Epoxide Ring Opening with NH Sulfoximines. Read more.
Blog
08/11/2022
Why studying the gut microbes could help to cure?
We explore the importance of Gut Microbes on our health by discussing five of those Gut-Organ Axis - brain, intestine, liver, lung, and skin. Read more here.
Publication scientifique
03/11/2022
Intranasal delivery of a chimpanzee adenovirus vector expressing a pre-fusion spike (BV-AdCoV-1) protects golden Syrian hamsters against SARS-CoV-2 infection
We investigated the efficiency of Vaccine Vector based on Chimpanzee Adenovirus in golden Syrian hamsters against SARS-Cov-2 infection. Learn more here.
Poster
01/11/2022
Translational pharmacology supporting biologics development in Oncology
Translational Pharmacology is responsible for connecting products of novel molecular research, such as Biologics, to the patients that need it. Learn more here.
Communiqué de Presse
19/10/2022
ERES IV acquires a majority stake in Oncodesign Services
ERES IV, advised by Elyan Partners, acquires a majority stake in Oncodesign Services and will file an offer on the company’s remaining shares. Find out more
Webinaire
13/10/2022
Fragment-Based Drug Discovery — Hitting Targets Using the Right Chemistry and Expertise Alliances
Learn about Fragment-Based Drug Discovery (FBDD) and its Applications in our Webinar with leading experts from the field of FBDD.
Communiqué de Presse
30/09/2022
The General Meeting of Oncodesign authorises the allocation of OPM
Each Oncodesign shareholder will receive one OPM share for one ONCODESIGN share held
Communiqué de Presse
28/09/2022
Euronext Paris authorises the listing of OPM shares
Oncodesign Precision Medicine (OPM) and Oncodesign announce that Euronext Paris S.A. has authorised the admission to listing on Euronext Access + market in Paris of OPM’s ordinary shares.